Abstract
Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.
Original language | English |
---|---|
Journal | Clinical Cancer Research |
Volume | 16 |
Issue number | 10 |
Pages (from-to) | 2872-80 |
Number of pages | 9 |
ISSN | 1078-0432 |
DOIs | |
Publication status | Published - 15 May 2010 |